Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment
This article provides a
short summary of last years’ findings targeting outcomes, limitations,
and adverse effects of these new therapeutic approaches. The results of recent
trials and case series pointed pembrolizumab as the most promising drug among
these new therapies. It is the most often used ICI and the one presenting the
best results with less related adverse effects when in comparison to the
standard treatment with mitotane. Hereafter, the identification of specific
molecular biomarkers or immune profiles associated with ICI or mTKI good
response will facilitate the selection of candidates for these therapies. So
far, microsatellite instability and Lynch Syndrome related germline mutations
are suggested as predictive biomarkers of good response. Contrarywise, cortisol
secretion has been associated with more aggressive ACC tumors and potentially
poor responses to immunotherapy. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Ara újo, Alexandra Novais Bugalho, Maria Jo ão Tags: Review Source Type: research
More News: Adrenocortical Carcinoma | Cancer & Oncology | Carcinoma | Endocrinology | HNPCC | Hormones | Immunotherapy | Lynch Syndrome | Toxicology